Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Highlights • TGFβ is a complex cytokine with both anti-tumor and oncogenic functions. • TGFβ blockade has demonstrated promising antitumor activity in various preclinical models. • The TGFβ pleiotropic role challenges its evaluation as a therapeutic target in clinical trials. • Different anti-TGFβ agents have been developed and tested in clinical trials with diverse and sometimes limited efficacies.
Background: Molecular screening in mCRC has demonstrated an impact in treatment selection and outcome estimation. KRAS mutations (mut) frequently coexist with PIK3CA mut. Molecular, clinical and prognostic association of the dKP group has not been studied in detail. Methods: 657 mCRC patient records that were eligible for targeted mut profile were reviewed.
Background: Anti-EGFR monoclonal antibodies (MoAb) should only be considered for treatment of patients with colorectal cancer (CRC) whose tumors are wild-type (WT) for RAS genes. Determination of RAS status based on circulating tumor DNA (ctDNA) is expected to offer advantages over standard tissue testing. Validation of concordance between plasma and tissue determination is critical to move ctDNA forward as a surrogate testing in clinical practice.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.